Jump Financial’s Dyne Therapeutics DYN Stock Holding History

Jump Financial’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$192K	Sell	10,610 -24,650	-70%	-$425K	﹤0.01%	1677
2025 Q4	$690K	Sell	35,260 -64,624	-65%	-$1.22M	0.01%	1148
2025 Q3	$1.26M	Buy	+99,884	New	+$1.14M	0.02%	907
2025 Q1	–	Sell	-50,911	Closed	-$1.2M	–	1685
2024 Q4	$1.2M	Buy	+50,911	New	+$1.51M	0.03%	684
2024 Q2	–	Sell	-27,382	Closed	-$777K	–	1912
2024 Q1	$777K	Buy	+27,382	New	+$619K	0.02%	939
2023 Q2	–	Sell	-24,064	Closed	-$277K	–	1884
2023 Q1	$277K	Sell	24,064 -9,291	-28%	-$121K	0.01%	1158
2022 Q4	$387K	Buy	33,355 +3,167	+10%	+$36.6K	0.02%	893
2022 Q3	$383K	Buy	+30,188	New	+$346K	0.01%	1014
2022 Q1	–	Sell	-19,100	Closed	-$227K	–	1633
2021 Q4	$227K	Buy	+19,100	New	+$268K	0.01%	1047

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Jump Financial's DYN Position: Q1 2026 in Review

Jump Financial reduced its Dyne Therapeutics (DYN) stake by 70% in Q1 2026, selling an estimated $425K and leaving 10,610 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #1677.

Jump Financial first reported a position in DYN in Q4 2021 and has held it in 9 quarters since. The position peaked at $1.26M in Q3 2025. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Jump Financial held 10,610 shares of Dyne Therapeutics worth $192K as of Q1 2026.
Jump Financial sold 24,650 Dyne Therapeutics shares in Q1 2026, an estimated $425K.
Dyne Therapeutics made up ﹤0.01% of Jump Financial's portfolio in Q1 2026, its #1677 holding.
Jump Financial first reported a position in Dyne Therapeutics in Q4 2021 and has held it in 9 quarters since.
Jump Financial's Dyne Therapeutics position peaked at $1.26M in Q3 2025.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.